22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Coagadex regulatory update

The European Commission approved Coagadex from Bio Products to treat and prevent bleeding episodes and for perioperative management in patients with hereditary Factor X deficiency. Last October, FDA approved the plasma-derived Factor X protein therapy...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

Coagadex regulatory update

EMA’s CHMP recommended approval of Coagadex from Bio Products to treat and prevent bleeding episodes and for perioperative management in patients with hereditary Factor X deficiency. Last October, FDA approved the plasma-derived Factor X protein...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Bio Products Laboratory sales and marketing update

Late last year, Bio Products Laboratory launched Coagadex in the U.S. for on-demand treatment and control of bleeding episodes in patients ages 12 and older with hereditary Factor X deficiency and for perioperative management of...
02:46 , Jan 30, 2016 |  BC Extra  |  Company News

CHMP backs basket of therapies

EMA's CHMP recommended marketing authorization of three new medicines Thursday and recommended label expansions for Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG) and Revolade eltrombopag from Novartis AG (NYSE:NVS; SIX:NOVN). CHMP backed Empliciti elotuzumab from Bristol-Myers...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Coagadex regulatory update

FDA approved a BLA for Coagadex from Bio Products for on-demand treatment and control of bleeding episodes in patients ages >=12 with hereditary Factor X deficiency and for perioperative management of bleeding in patients ages...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Subgam-VF: Phase III started

Bio Products began the open-label, U.S. Phase III SCIG03 trial to evaluate weekly subcutaneous Subgam-VF for up to 26 weeks in about 35 patients. Bio Products Laboratory Ltd. , Elstree, U.K.   Product: Subgam-VF  ...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Coagadex regulatory update

FDA accepted for review an amended BLA for Coagadex from Bio Products to treat hereditary Factor X deficiency. The PDUFA date is Oct. 27. An MAA for the plasma-derived Factor X protein therapy is also...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

Factor X coagulation product: Phase III data

Bio Products Laboratory said the criteria for treatment success were met in an open-label Phase III trial in 16 patients with severe or moderate hereditary Factor X deficiency evaluating the company’s Factor X coagulation product....